The correct answer is D. Absence of reports of cutaneous atrophy.

Tacrolimus and pimecrolimus are non-steroid anti-inflammatory drugs and are not associated with side effects reported with use of topical corticosteroids, including atrophy, striae formation, telangiectasias, cataracts, and HPA axis suppression.

Topical calcineurin inhibitors can be cost prohibitive, can cause irritation and/or burning, are typically used twice a day and do not typically have a quicker onset than topical steroids.

References: Dermatitis. 2015 May-Jun;26(3):122-32.
Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis.
Chia BK, Tey HL. [https://www.ncbi.nlm.nih.gov/pubmed/25984688]